Education
About Us
Working with TipRanks
Follow Us
Legend Biotech Corporation (LEGN)
NASDAQ:LEGN
LEGN Stock Chart & Stats
$17.75
-$0.50(-1.49%)
At close: 4:00 PM EST
$17.75
-$0.50(-1.49%)
Day’s Range― - ―
52-Week Range$16.24 - $45.30
Previous CloseN/A
Volume249.07K
Average Volume (3M)2.44M
Market Cap
$3.28B
Enterprise Value$1.88B
Total Cash (Recent Filing)$992.59M
Total Debt (Recent Filing)$410.24M
Price to Earnings (P/E)―
Beta0.61
Next Earnings
Mar 10, 2026EPS Estimate
<0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.11
Shares Outstanding184,570,710
10 Day Avg. Volume2,198,524
30 Day Avg. Volume2,440,130
Financial Highlights & Ratios
PEG Ratio0.25
Price to Book (P/B)2.86
Price to Sales (P/S)4.74
P/FCF Ratio-18.81
Enterprise Value/Market Cap0.57
Enterprise Value/Revenue2.07
Enterprise Value/Gross Profit3.42
Enterprise Value/Ebitda-10.27
Forecast
1Y Price Target
$56.59Price Target Upside218.82% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
EPS Forecast (FY)0.43
Revenue Forecast (FY)$1.48B
Bulls Say, Bears Say
Bulls Say
Clinical DurabilityAnalyst underscores CARVYKTI's deep, durable remissions and five‑year functional cure evidence, positioning the therapy as a curative option that can free patients from continuous treatment and differentiate it from chronic competitors.
Commercial AdoptionAnalyst highlights CARVYKTI's growing adoption across both early and late treatment settings and entrenched physician use, creating a robust commercial foundation that supports revenue expansion and market leadership.
Regulatory MoatAnalyst points to recent regulator comments raising the evidentiary bar for me‑too CAR‑T programs, which strengthens CARVYKTI's regulatory moat and makes it harder for later entrants to replicate its position.
Bears Say
Operational And Governance RisksAnalyst highlights risks such as potential manufacturing expansion failures, partnership complications, and accounting or control issues that could disrupt operations and hurt the company's outlook.
Safety Concerns Limiting UptakeAnalyst cites worries about delayed neurotoxicity and colitis that are deterring physicians from using CARVYKTI in community settings and slowing patient uptake.
Sales And Demand WeaknessAnalyst reports CARVYKTI sales fell short of market expectations, indicating weaker-than-anticipated demand that could pressure revenue momentum and investor sentiment.
Legend Biotech News
LEGN FAQ
What was Legend Biotech Corporation’s price range in the past 12 months?
Legend Biotech Corporation lowest stock price was $16.24 and its highest was $45.30 in the past 12 months.
What is Legend Biotech Corporation’s market cap?
Legend Biotech Corporation’s market cap is $3.28B.
When is Legend Biotech Corporation’s upcoming earnings report date?
Legend Biotech Corporation’s upcoming earnings report date is Mar 10, 2026 which is in 3 days.
How were Legend Biotech Corporation’s earnings last quarter?
Legend Biotech Corporation released its earnings results on Nov 12, 2025. The company reported -$0.11 earnings per share for the quarter, missing the consensus estimate of -$0.073 by -$0.037.
Is Legend Biotech Corporation overvalued?
According to Wall Street analysts Legend Biotech Corporation’s price is currently Undervalued.
Does Legend Biotech Corporation pay dividends?
Legend Biotech Corporation does not currently pay dividends.
What is Legend Biotech Corporation’s EPS estimate?
Legend Biotech Corporation’s EPS estimate is <0.01.
How many shares outstanding does Legend Biotech Corporation have?
Legend Biotech Corporation has 184,570,710 shares outstanding.
What happened to Legend Biotech Corporation’s price movement after its last earnings report?
Legend Biotech Corporation reported an EPS of -$0.11 in its last earnings report, missing expectations of -$0.073. Following the earnings report the stock price went down -2.654%.
Which hedge fund is a major shareholder of Legend Biotech Corporation?
Currently, no hedge funds are holding shares in LEGN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Legend Biotech Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$56.59 (218.82% Upside)
$56.59 (218.82% Upside)
Blogger Sentiment
Bullish
LEGN Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 3.0M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▼ 0.4%
Last 30 Days ▼ 0.2%
Last 30 Days ▼ 0.2%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-48.84%
12-Months-Change
Fundamentals
Return on Equity
-22.60%
Trailing 12-Months
Asset Growth
-1.32%
Trailing 12-Months
Company Description
Legend Biotech Corporation
Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery and development of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM), as well as a comparison of the treatment with standard triplet therapy in revlimid-refractory multiple myeloma. The company also has a portfolio of earlier-stage autologous product candidates, which are in Phase I clinical trials for the treatment of gastric cancer and T cell lymphoma. In addition, it is developing CAR-T product candidates targeting CD20/CD22/CD19 for the treatment of non-hodgkins lymphoma, diffuse large B-cell lymphoma, and acute lymphoblastic leukemia. Further, the company has product candidates in early preclinical and clinical development for the treatment of solid tumors as well as infectious diseases. It has collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of ciltacabtagene autoleucel. Legend Biotech Corporation was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation is a subsidiary of Genscript Biotech Corporation.
LEGN Company Deck
LEGN Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects a largely positive outlook driven by significant sales growth of CARVYKTI, successful international expansion, and advancements in clinical trials and manufacturing capacity. However, challenges like managing neurotoxicity and achieving profitability remain.View all LEGN earnings summariesLEGN Stock 12 Month Forecast
Average Price Target
$56.59
▲(218.82% Upside)
Technical Analysis
Cytokinetics
―
Axsome Therapeutics
―
Rhythm Pharmaceuticals
―
Atrium Therapeutics, Inc.
―
Abivax SA Sponsored ADR
―
Ownership Overview
―
Insiders
14.57% Mutual Funds
5.94% Other Institutional Investors
76.58% Public Companies and Individual Investors